JWJohn Walker

John Walker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John Walker has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Vickie Elaine Baracos

    Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada

    3 shared publications
  • Angela Chan

    Département d'oncologie (Abdel-Rahman, Steed, Walker), University of Alberta, Cross Cancer Institute; Département de pharmacologie (McFarlane), University of Alberta, Edmonton, Alb.; Département d'oncologie (Ohm, Chan), University of British Columbia, Vancouver, C.-B.; Département d'oncologie (Loewen), University of Calgary, Arthur Child Comprehensive Cancer Centre, Calgary, Alb.; Département d'obstétrique et de gynécologie (Litalien), University of Alberta, Edmonton, Alb

    2 shared publications
  • Ariane Litalien

    Département d'oncologie (Abdel-Rahman, Steed, Walker), University of Alberta, Cross Cancer Institute; Département de pharmacologie (McFarlane), University of Alberta, Edmonton, Alb.; Département d'oncologie (Ohm, Chan), University of British Columbia, Vancouver, C.-B.; Département d'oncologie (Loewen), University of Calgary, Arthur Child Comprehensive Cancer Centre, Calgary, Alb.; Département d'obstétrique et de gynécologie (Litalien), University of Alberta, Edmonton, Alb

    2 shared publications
  • Brennan Olson

    Mayo Clin, Dept Otolaryngol Head & Neck Surg, Rochester, MN USA

    2 shared publications
  • Brock Debenham

    Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada

    2 shared publications
  • Carrie Ye

    McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary , Calgary AB

    2 shared publications

Latest Publications

  • Open Access

    Les avancées dans le traitement du cancer nécessitent des changements de toute urgence dans les effectifs en oncologie

    by Omar Abdel-Rahman, Ethan McFarlane, Hyejee Ohm, Angela Chan, Shaun Loewen, Ariane Litalien, Helen Steed, John Walker

  • Open Access

    Advances in cancer therapy require urgent changes to the oncology workforce

    by Omar Abdel-Rahman, Ethan McFarlane, Hyejee Ohm, Angela Chan, Shaun Loewen, Ariane Litalien, Helen Steed, John Walker


  • Open Access

    Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events

    by Khashayar Esfahani, John Walker, Kevin Bambury, Eoin O’carroll, Stephanie Snow

    The advent of immune checkpoint inhibitors (ICIs) has significantly transformed cancer treatment outcomes. However, these therapies can induce immune-related adverse events (irAEs) that may affect any organ system, sometimes requiring specialized expertise. As ICIs are increasingly used across various tumor types and in earlier treatment settings, not all practitioners have the necessary support network to handle complex irAEs. To address this gap, we collaborated with ONCOassist, a leading app for oncology professionals, to establish the first virtual Canadian Community of Practice (CoP) focused on irAEs. The CoP facilitates continuous learning and improves patient care among Canadian clinicians treating patients with immunotherapy by providing a platform for knowledge exchange and peer-to-peer support. This article outlines the development and growth of the CoP on irAEs, highlighting both successes and challenges. As of May 2024, over a year since its inception, the CoP on irAEs has attracted almost 130 Canadian oncology healthcare professionals, and peer-to-peer interactions and engagement continue to increase. To ensure its long-term sustainability, we plan to evolve and adapt the CoP to meet the needs of the oncology community and address clinical challenges associated with new therapies.

  • Open Access

    Assessing the effects of immune checkpoint inhibitors on bone utilizing machine learning–assisted opportunistic quantitative computed tomography

    by Bryn E Matheson, Jacob L Jaremko, Alexandra Dowhanik, Jasmine Gill, Cassandra Gallant, John Walker, Nathan Armani, William D Leslie, Michael Kolinsky, Steven K Boyd, et al.

    Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, yet their impact on bone health remains unclear. This study aimed to perform a retrospective cohort study utilizing routine CT scans from patients with melanoma to perform opportunistic QCT analysis to investigate the effects of ICI treatment on skeletal health, including volumetric BMD (vBMD) measurements and osteoarthritis (OA) parameters. A previously established machine learning-assisted opportunistic QCT pipeline was used to estimate lumbar spine vBMD from baseline and 12-mo follow-up CT scans in patients with melanoma treated with ICI therapy and those not treated with ICI therapy. Facet joint OA, osteophyte formation, and endplate sclerosis were also graded. Independent and paired t tests were used to determine any differences in vBMD and OA parameters between ICI users and non-ICI users. Multivariable linear regression models were used to control for confounding variables. Non-ICI users had a significant decrease in vBMD of −6.96 mg/cm3 from baseline to follow-up, whereas the ICI users had no significant change. There was a significant difference in change in vBMD from baseline to follow-up between the 2 groups, with the non-ICI users experiencing a 11.22 mg/cm3 larger decrease in vBMD. After adjusting for baseline age, sex, baseline vBMD, and change in OA parameters, this difference remained significant at −13.04 mg/cm3. Among the ICI users, those who had a decline in vBMD had a lower baseline vBMD compared with those who had increased vBMD. Neither group showed a significant change in OA parameters over the follow-up period, nor a difference in change between ICI and non-ICI users, even after adjusting for sex, age, and baseline OA parameters. While the effects of ICI treatment on vBMD may vary based on baseline bone health, ICIs do not significantly impact OA parameters in the short term.


  • Sarcopenia etymology: Sarcos (flesh) penia (poverty) i.e. absence, lack or deficiency of a body constituent

    by Catherine Kubrak, Lisa Martin, Aaron J. Grossberg, Brennan Olson, Faith Ottery, Merran Findlay, Judith D. Bauer, Naresh Jha, Rufus Scrimger, Brock Debenham, et al.


  • Open Access

    Quantifying the severity of sarcopenia in patients with cancer of the head and neck

    by Catherine Kubrak, Lisa Martin, Aaron J. Grossberg, Brennan Olson, Faith Ottery, Merran Findlay, Judith D. Bauer, Naresh Jha, Rufus Scrimger, Brock Debenham, et al.


  • Open Access

    Weighted Trajectory Analysis and Application to Clinical Outcome Assessment

    by Utkarsh Chauhan, Kaiqiong Zhao, John Walker, John R. Mackey

    The Kaplan–Meier (KM) estimator is widely used in medical research to estimate the survival function from lifetime data. KM estimation is a powerful tool to evaluate clinical trials due to simple computational requirements, its use of a logrank hypothesis test, and the ability to censor patients. However, KM estimation has several constraints and fails to generalize to ordinal variables of clinical interest, such as toxicity and ECOG performance. We devised weighted trajectory analysis (WTA) to combine the advantages of KM estimation with the ability to visualize and compare treatment groups for ordinal variables and fluctuating outcomes. To assess statistical significance, we developed a new hypothesis test analogous to the logrank test. We demonstrated the functionality of WTA through 1000-fold clinical trial simulations of unique stochastic models of chemotherapy toxicity and schizophrenia disease course. With increments in sample size and hazard ratio, we compared the performance of WTA to KM estimation and the generalized estimating equation (GEE). WTA generally required half the sample size to achieve comparable power to KM estimation; advantages over the GEE included its robust nonparametric approach and summary plot. We also applied WTA to real clinical data: the toxicity outcomes of melanoma patients receiving immunotherapy and the disease progression of patients with metastatic breast cancer receiving ramucirumab. The application of WTA demonstrated that using traditional methods such as KM estimation can lead to both type I and II errors by failing to model illness trajectory. This article outlines a novel method for clinical outcome assessment that extends the advantages of Kaplan–Meier estimates to ordinal outcome variables.


  • Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event

    by Carrie Ye, Kevin Lee, William D. Leslie, Mu Lin, John Walker, Michael Kolinsky

    Introduction T cell activation can lead to osteoporosis and while there are several case reports of fractures occurring after immune checkpoint inhibitor (ICI) use, to date, there are no population level studies looking at fracture risk related to ICI use. Methods Using Alberta Cancer Registry data, we identified all individuals treated with ICI for cancer between September 29, 2010, and March 31, 2019. Linked records from Alberta’s healthcare administrative databases were assessed for the presence of fracture diagnostic codes in the year prior to and up to two years after ICI initiation. Fracture rate was stratified based on the time-period before and after ICI initiation. Fracture rates after ICI were compared to baseline. Results The study cohort consisted of 1600 ICI users (mean age 65.7 years, 60% male). Most patients were treated with an anti-PD-1 agent (73.9%). ICIs were initiated on average 707.8 days after cancer diagnosis. 76 (4.8%) individuals had a remote history of a major fracture, and 141 (8.8%) had been treated with an osteoporosis medication prior to ICI treatment. The fracture rate in the year prior to ICI initiation was 11.3 per 1000 patient-years. The fracture rate in the year after ICI initiation was significantly higher at 27.3 per 1000 patient-years. The fracture rate dropped to 17.6 per 1000 patient-years in the second year after ICI initiation. The incidence rate ratio of sustaining a major fracture in the year after compared to the year prior to ICI initiation was 2.43 (95% CI 1.34–4.27). Conclusions Fracture risk may be increased in cancer patients early after initiation of ICI, and this may represent a novel immune-related adverse event.


  • Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer

    by Martine J. Sealy, Tanadech Dechaphunkul, Cees P. van der Schans, Wim P. Krijnen, Jan L.N. Roodenburg, John Walker, Harriët Jager-Wittenaar, Vickie E. Baracos